TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

TCR2 Therapeutics Inc.

Adaptimmune is focused on treating solid tumors utilizing a proprietary cell therapy platform that harnesses a patient's cells to combat cancer. This approach is self-described as having the potential to improve the patient experience.

NASDAQ:TCRR

Adaptimmune

Last Close

1.48

31/05 20:00

Market Cap

58.11M

Beta: 1.93

Volume Today

3.75M

Avg: 613.64K

PE Ratio

−0.36

PFCF: −0.47

Filings Not Available